Blockchain Registration Transaction Record
Quantum BioPharma Advances MS Treatment with UK Regulatory Submission
Quantum BioPharma submits Lucid-MS to UK's ILAP program, aiming to accelerate access to groundbreaking MS treatment. Learn more about this innovative approach.

This development is crucial for the millions affected by multiple sclerosis worldwide, offering hope for a faster route to innovative treatments. Quantum BioPharma's submission to the ILAP program represents a potential leap forward in MS therapy, emphasizing the importance of streamlined regulatory processes in bringing life-changing medications to patients sooner. The progress of Lucid-MS could significantly impact the treatment landscape for MS, showcasing the value of strategic partnerships and regulatory innovation in healthcare.
Blockchain | Details |
---|---|
Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
Transaction ID | 0x5aafd8cc592d80a4363511dc0d0e6ab620e8f6efa40064d7bec15c67de455c1a |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | ovalhQma-0b70ed68017ee5aa45ffc081b961cfe6 |